FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANG	GES IN BE	<b>NEFICIAL</b> (	<b>DWNERSHIP</b>

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

												00.0							
Name and Address of Reporting Person*     Secora Michael			<u>R</u>	2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. RXRX								Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director					vner		
(Last)	(F	irst)	(Middle)											X	below)	•		below)	
C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET				3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023									Cł	nief Fina	ncial	Officer			
(Street) SALT LA	AKE U	Т	84101		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
		Та	ble I - Nor	n-Deri	vativ	ve Se	ecuritie	s Ac	quired,	Dis	osed c	of, or Be	nefic	ially	Owned				
Date			Date	th/Day/Year)   Exe		Execution if any	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Of Code (Instr.		ies Acquired (A) o Of (D) (Instr. 3, 4				s lly ollowing	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) (D)	Pri	се	Transacti (Instr. 3 a				(111501.4)	
Class A Common Stock			02/0	1/2023				A <sup>(1)</sup>		202,428 A S		\$	0.00	790,502(2)			D		
Class A Common Stock			02/0	01/2023				A <sup>(3)</sup>		7,735 A S		\$	0.00	0 798,237		D			
Class A Common Stock 02/0			01/2023						2,669 D S		\$	8.55	795,568		B D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any Code (Instr.		S. Number of Derivative Securities   Expiration Date (Month/Day/Year)   Securities   Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			ties ig e Securi	Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)							
				Co	Code	v	(A)		Date Exercisab		xpiration ate	Title	Amou or Numb of Sha	er		(Instr. 4)			
Stock Option (Right to	\$8.55	02/01/2023			A		404,857		(5)	0.	2/01/2033	Class A Common Stock	404,8	857	\$0.00	404,857		D	

## Explanation of Responses:

- 1. This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter.
- $2.\ Includes\ 1,\!502\ shares\ purchased\ pursuant\ to\ the\ Issuer's\ Employee\ Stock\ Purchase\ Plan\ on\ May\ 20,\ 2022.$
- 3. This RSU vested immediately upon the grant date.
- 4. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
- 5. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

## Remarks:

/s/ Nathan Hatfield, attorney-infact

\*\* Signature of Reporting Person

02/03/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.